Ua hoʻopau ʻo Epiprobe ma kahi o RMB 100 miliona o ke kālā Series B

I kēia mau lā, ua hoʻolaha ʻo Shanghai Epiprobe Biotechnology Co., Ltd. (e ʻike ʻia ʻo "Epiprobe") ua hoʻopau ʻo ia ma kahi o RMB 100 miliona ma ke kālā Series B, i hui pū ʻia e ka ʻoihana ʻoihana, nā waihona kālā aupuni a me ka hui inoa ʻo Yiyi Shares (SZ). :001206).

Hoʻokumu ʻia ma 2018, ʻo Epiprobe, ma ke ʻano he mea kākoʻo a he paionia o ka nānā ʻana i ka pan-cancer mua, he ʻoihana ʻenehana kiʻekiʻe e kālele ana i ka maʻi maʻi molecular a me ka ʻoihana lāʻau lapaʻau pololei.Ke kūkulu nei ma luna o ka hui kiʻekiʻe o ka poʻe loea epigenetics a me ka hōʻiliʻili hoʻonaʻauao hohonu, ʻimi ʻo Epiprobe i ke kahua o ka ʻike ʻana i ka maʻi kanesa, kākoʻo i ka ʻike o "ka mālama ʻana i nā mea āpau mai ka maʻi kanesa," i hoʻopaʻa ʻia i ka ʻike mua ʻana, ka ʻike mua a me ka mālama mua ʻana i ka maʻi kanesa, a laila e hoʻomaikaʻi ai i ke ola. ka helu o nā maʻi maʻi maʻi e hoʻonui i ke olakino o ka lehulehu holoʻokoʻa.

Ma hope o ka ʻeli ʻana no 20 mau makahiki, ua ʻike kūʻokoʻa ka hui koʻikoʻi o Epiprobe i ke ʻano o ka maʻi maʻi Aligned General Methylated Epiprobes (TAGMe), ka mea maʻamau i nā maʻi maʻi maʻi like ʻole, no laila e hoʻonui nui ai i ke kahua noi.

E pili ana i ka ʻenehana ʻike, ua manaʻo ʻia ka pyrosequencing ma ke ʻano he "gold standard" no ka methylation detection, akā naʻe e hilinaʻi nei i ka hoʻololi ʻana i ka bisulfite, akā e hōʻike ana i nā hemahema e like me ka hiki ke hoʻololi ʻole, maʻalahi DNA degradation, koi kiʻekiʻe no nā mea hana, a me ka hilinaʻi ʻana i nā mea waiwai.Ke kaupalena nei kēia mau hemahema i kāna noi.ʻO Epiprobe, ma o ka hana ʻana i nā holomua ʻenehana, ua hoʻomohala kūʻokoʻa i kahi ʻenehana ʻike methylation hou - Me-qPCR me ka mālama ʻole ʻana i ka bisulfite, e hoʻemi ana i ke kumukūʻai a hoʻomaikaʻi i ka paʻa ʻana o ka ʻike a me ka operability clinical, e hana maʻalahi a maʻalahi ka ʻike.

ʻO Epiprobe, e kau ana ma luna o nā hōʻailona pan-cancer koʻikoʻi o ka hui a me nā ʻano ʻike ʻike methylation, ua noi ma luna o 50 mau palapala ʻāina a me ka honua, a ua loaʻa iā ia nā mana e hoʻokumu i kahi patent paʻa paʻa.

I kēia manawa, ua hana pū ʻo Epiprobe me ka ʻoi aku o 40 mau halemai kiʻekiʻe ma Kina, me ka Halemai Zhongshan, International Peace Maternity and Child Health Hospital, a me Changhai Hospital etc. , ka ma'i 'a'ai urothelial (me ka ma'i 'a'ai ma'i ma'i, ka ma'i 'a'ai ureteral, ka ma'i 'a'ai pelvis renal), ka ma'i 'a'ai māmā, ka ma'i 'a'ai thyroid, ka ma'i 'a'ai hematological a me nā ma'i ma'i 'ē a'e.Ua hoʻokō ʻia ka hōʻoia ʻelua makapō ma 70,000 mau hōʻailona lapaʻau me ka huina o 25 mau ʻano maʻi maʻi.

Ma waena o nā huahana, no ka wahine reproductive tract cancer detection products, ua hoʻokō ʻia ka hōʻoia ʻelua-makapō ma luna o 40,000 mau lāʻau lapaʻau, a ua paʻi ʻia kahi ʻano o nā hopena noiʻi i loko o nā puke moʻolelo hoʻonaʻauao kaulana e like me Cancer Research, Clinical and Translational Medicine, a ke hoʻokō ʻia nei nā hoʻokolohua lapaʻau nui-nui.Ke holomua nei ka R&D a me ka hoʻonui mau ʻana i nā kumuwaiwai, ke piʻi mau nei ka pipeline huahana o ka hui.

Ua ʻōlelo ʻo Ms. Hua Lin, Luna Nui o Epiprobe: “He hanohano nui ko mākou ʻike ʻia a kākoʻo ʻia e nā poʻokela ʻoihana maikaʻi loa.Hōʻike ʻia ʻo Epiprobe e kāna hōʻiliʻili hoʻonaʻauao hohonu, ʻenehana kūʻokoʻa, a me ka noiʻi lapaʻau paʻa, i lanakila ai ka hilinaʻi o nā ʻaoʻao he nui.I nā makahiki ʻehā i hala iho nei, ua hoʻomaikaʻi nui ka hui a me nā hana.I nā lā e hiki mai ana, ʻaʻole mākou e hoʻāʻo e kono aku i nā hoa like like ʻole e hui pū me ka hana pū ʻana, a laila e hoʻolaha mau nei i ke kaʻina noi R&D a me ka hoʻopaʻa inoa ʻana, a me ka hāʻawi ʻana i nā kauka a me nā mea maʻi i nā lawelawe hoʻāʻo maʻi maʻi maikaʻi loa. huahana."